Poster
147
(#147) Inpatient Length of Stay and Healthcare Professional Preferences for Initiating TV-46000, a Long-Acting Subcutaneous Antipsychotic, or Intramuscular Paliperidone Palmitate in Patients Hospitalized With Schizophrenia
Psych Congress 2025
Abstract: Background: Initiation requirements for long-acting injectable antipsychotics (LAIs) vary and may influence healthcare resource utilization and ease of use in patients hospitalized with schizophrenia. This study compared outcomes and healthcare professional (HCP) perceptions following initiation of TV-46000, a long-acting subcutaneous formulation of risperidone (single-dose initiation), versus once-monthly intramuscular paliperidone palmitate (PP1m; two-dose initiation).
Methods: A retrospective observational cohort study included HCPs who prescribed TV-46000 or PP1m for patients with schizophrenia during hospitalization. HCPs completed a survey and provided patient data matched on demographics/clinical characteristics. Outcomes included length of stay (LOS), second-dose adherence for PP1m, and HCP ease-of-use preferences.
Results: Data were collected from 58 HCPs covering patients initiating TV-46000 (n=150) or PP1m (n=150). The study analyzed data from 137 patients who initiated TV-46000 during hospitalization and 94 patients who initiated PP1m and completed the initiation regimen during hospitalization. TV-46000 was associated with a 2.89-day shorter LOS compared with PP1m (12.57 [SD:10.03] vs 15.46 days [10.15], P=.033), which translates to estimated direct cost savings of $3200 per hospitalization. Among patients starting PP1m, 91% completed the required 2-dose initiation, with 22% receiving the second dose after discharge. More HCPs favored TV-46000 over PP1m for ease of administration (45% vs 34%), initiation (47% vs 33%), dosing characteristics (40% vs 38%), and subcutaneous injection features (40% vs 33%). Overall, 45% preferred TV-46000, while 38% preferred PP1m.
Conclusions: Initiation of TV-46000 was associated with shorter hospital stays and favorable HCP perceptions compared to PP1m, potentially offering cost savings due to its dosing characteristics and convenience.
Short Description: This study compared outcomes in patients hospitalized with schizophrenia and healthcare professional (HCP) preferences for 2 long-acting injectable antipsychotics with different initiation requirements: TV-46000 (1 dose) and intramuscular paliperidone palmitate (PP1m; 2 doses separated by 4-7 days). TV-46000 was associated with shorter hospital stays translating into potential cost savings, and higher HCP satisfaction regarding ease of use and dosing.
Name of Sponsoring Organization(s): Teva Branded Pharmaceutical Products R&D LLC
Methods: A retrospective observational cohort study included HCPs who prescribed TV-46000 or PP1m for patients with schizophrenia during hospitalization. HCPs completed a survey and provided patient data matched on demographics/clinical characteristics. Outcomes included length of stay (LOS), second-dose adherence for PP1m, and HCP ease-of-use preferences.
Results: Data were collected from 58 HCPs covering patients initiating TV-46000 (n=150) or PP1m (n=150). The study analyzed data from 137 patients who initiated TV-46000 during hospitalization and 94 patients who initiated PP1m and completed the initiation regimen during hospitalization. TV-46000 was associated with a 2.89-day shorter LOS compared with PP1m (12.57 [SD:10.03] vs 15.46 days [10.15], P=.033), which translates to estimated direct cost savings of $3200 per hospitalization. Among patients starting PP1m, 91% completed the required 2-dose initiation, with 22% receiving the second dose after discharge. More HCPs favored TV-46000 over PP1m for ease of administration (45% vs 34%), initiation (47% vs 33%), dosing characteristics (40% vs 38%), and subcutaneous injection features (40% vs 33%). Overall, 45% preferred TV-46000, while 38% preferred PP1m.
Conclusions: Initiation of TV-46000 was associated with shorter hospital stays and favorable HCP perceptions compared to PP1m, potentially offering cost savings due to its dosing characteristics and convenience.
Short Description: This study compared outcomes in patients hospitalized with schizophrenia and healthcare professional (HCP) preferences for 2 long-acting injectable antipsychotics with different initiation requirements: TV-46000 (1 dose) and intramuscular paliperidone palmitate (PP1m; 2 doses separated by 4-7 days). TV-46000 was associated with shorter hospital stays translating into potential cost savings, and higher HCP satisfaction regarding ease of use and dosing.
Name of Sponsoring Organization(s): Teva Branded Pharmaceutical Products R&D LLC
